Home >Industry >Manufacturing >Cadila, Depomed settle US patent dispute on neuro pain drug Gralise

Mumbai: Ahmedabad-based drug maker Cadila Healthcare Ltd said on Tuesday that it has settled a patent infringement case with US drug maker Depomed Inc., ending a litigation related to Depomed’s neuropathic pain drug Gralise.

With this settlement, the Indian company can launch its generic version of Gralise, also known as gabapentin, in the US market soon after the expiry of Depomed’s original patent in February 2024 or even before that under the terms of the agreement.

Depomed posted sales of $36.2 million in 2013 for Gralise.

Shares of Cadila Healthcare closed at 976.851, up 1.03% on Tuesday, while the benchmark Sensex closed down 0.64% at 22,484.93 points.

Subscribe to Mint Newsletters
* Enter a valid email
* Thank you for subscribing to our newsletter.

Never miss a story! Stay connected and informed with Mint. Download our App Now!!

Edit Profile
My ReadsRedeem a Gift CardLogout